Lophius Biosciences GmbH, a Regensburg, Germany-based biotech company, completed a €4.25m financing round.
The round was led by VRD GmbH, with participation from the Bavarian Growth Fund (Wachstumsfonds Bayern) of Bayern Kapital, Wolf Biotech GmbH and WIC GmbH.
The company intends to use the funds to expand its in-vitro diagnostic programs to tuberculosis as well to further strengthen the market penetration activities for its T Cell Tool and contract research portfolio.
Led by Bernd Merkl and Robert Phelps, co-CEOs and Managing Directors, Lophius Biosciences focuses on the development and marketing of innovative T cell-based Research Tools, Contract Research Solutions and Diagnostics for functional assessment of pathogen/disease-reactive T cells.
The diagnostic development program for tuberculosis (TB) is based on the company’s proprietary Reverse T Cell Technology, which enables the differentiation of in-vivo activated T cells versus T memory cells and hence. In case of TB, it allows the identification of patients with a contagious active disease and individuals having only a latent infection.